Location Directory

Clinical trials in Nashville, Tennessee

This page shows live ClinicalTrials.gov search results for Nashville, Tennessee, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10867

Shown on this page

Current sort

Institutions in Nashville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Vanderbilt University Medical Center

Live official records

Open in full search

Conditions: Melanoma, Cutaneous Malignant, Mucosal Melanoma
Interventions: IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel; Biological · Drug
Lead sponsor: Immatics US, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 43
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more

Conditions: Microvascular Inflammation
Interventions: Felzartamab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 25
States / cities: Loma Linda, California • Los Angeles, California • Orange, California + 19 more

Conditions: Depression
Interventions: Web-App based Lifestyle Physical Activity Promotion Program, The Centers for Disease Control and Prevention (CDC) website on depression and physical activity guidelines; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mitral Valve Regurgitation
Interventions: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2036
U.S. locations: 78
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 57 more

Conditions: Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 158
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more

Conditions: Solid Tumors
Interventions: INCB161734, Placebo, Investigator's choice of chemotherapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 69
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 55 more

Conditions: Clostridoides Difficile Associated Disease
Interventions: C.difficile vaccine, Saline Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 32,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 142
States / cities: Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 90 more

Conditions: Prostate Cancer, Prostatic Neoplasms
Interventions: Ifinatamab deruxtecan, Docetaxel, Prednisone, Rescue Medication; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 55
States / cities: Phoenix, Arizona • Clovis, California • Duarte, California + 43 more

Conditions: Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Interventions: NEU-411, Placebo; Drug · Other
Lead sponsor: Neuron23 Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 45
States / cities: Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more

Conditions: Myeloproliferative Neoplasms
Interventions: INCA036978, Standard disease-directed therapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 23
States / cities: Birmingham, Alabama • Irvine, California • Los Angeles, California + 17 more

Conditions: Diabetic Macular Edema (DME)
Interventions: Remigromig, Ranibizumab; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 107
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 96 more

Conditions: Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Interventions: Cemsidomide, Dexamethasone; Drug
Lead sponsor: C4 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 25
States / cities: Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more

Clinical trials in Nashville, Tennessee

Filter and sort this location

Institutions in Nashville

Live official records

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

To Improve Depressive Symptoms Using a Web-App

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma